In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kala Pharmaceuticals Inc.

www.kalarx.com

Latest From Kala Pharmaceuticals Inc.

Kala Needs Big STRIDE To Get Dry Eye Drug OK

The US FDA has issued a complete response letter for KPI-121 but Kala hopes to resubmit the drug during the first half of next year backed by data from the ongoing STRIDE 3 study.

Ophthalmic Strategy

Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Complete Response Letters

Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy

The latest drug development news and highlights from our FDA Performance Tracker.

Drug Review Approvals

Finance Watch: With The Year's Biggest IPO, CFO Says Allogene Is Ready To Go 'Full Throttle'

Allogene launched a $324m IPO to fund development of its allogeneic CAR-T pipeline, bringing its 2018 fundraising total to $744m. Also, GW Pharma's $345m offering tops recent follow-ons.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Topical Delivery
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Kala Pharmaceuticals Inc.
  • Senior Management
  • Mark Iwick, Chmn. & CEO
    Mary Reumuth, CFO
    Kim Brazzell, PhD, CMO
    Hongming Chen, CSO
  • Contact Info
  • Kala Pharmaceuticals Inc.
    Phone: (781) 996-5252
    100 Beaver St.
    Ste. 201
    Waltham, MA 02453
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register